Robert brings more than 25 years of experience with demonstrated excellence in building operational excellence with a track record of success leading both small and large organizations. He has an extensive and successful commercialization track record across multiple therapeutic areas including cardiovascular disease.
Prior to joining InCarda, he was Chief Commercial Officer at Arena Pharmaceuticals, a clinical stage company developing treatments for auto-immune and cardiovascular disease. Arena was acquired by Pfizer on March 11, 2022, for $6.7 billion.
Over the course of his career Robert has worked on multiple block-buster cardiovascular therapeutics. Prior to Arena Pharmaceuticals, he was General Manager at Regeneron leading their US based Inflammation and Cardiovascular business. Robert spent nearly four years at Daiichi-Sanyko as SVP, CCO with responsibility for their US based cardiovascular and oncology therapeutics, overseeing nearly $3 billion in annual revenue.
From 2005-2014, Robert was at Amgen and served in US, EU and Global leadership roles. Robert worked across the Amgen portfolio during his tenure. He served in key leadership roles for Enbrel and Prolia, two of Amgen’s most successful products.
Robert began his career with Janssen Pharmaceuticals, a division of Johnson and Johnson and spent more than 10 years there in various sales, sales leadership and marketing roles. He received a B.S. degree in finance and economics at the State University of New York at Albany.